The Spain Endoscopic Submucosal Dissection/ESD Market was valued at $5.2 Million in 2025 and projected to reach to $7.6 Million by 2030, representing a compound annual growth rate of 8.0%. Spain's ESD market is positioned for steady growth as the country's healthcare system prioritizes advanced endoscopic interventions for early-stage gastrointestinal malignancies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Spain's ESD market is valued at $5.2 million in 2025 and is projected to reach $7.6 million by 2030, demonstrating consistent market expansion driven by healthcare modernization and increased procedural adoption.
The Spanish ESD market maintains an 8.0% CAGR from 2025-2030, slightly below the global average of 8.4%, reflecting Spain's mature healthcare infrastructure and selective adoption patterns in minimally invasive gastroenterology.
Spain's public healthcare system (SNS) continues to invest in advanced endoscopic technologies, with increasing budget allocations for gastrointestinal cancer treatment and prevention, supporting ESD procedure uptake across major medical centers.
Spanish gastroenterologists are increasingly adopting ESD techniques as an alternative to traditional surgical resection, driven by patient preference for reduced morbidity, shorter hospital stays, and improved quality of life outcomes.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | KNIVES (Product) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8.4% from 2025 to 2030 |
| Largest Segment | GASTROSCOPES & COLONOSCOPES (Product) |
| Market Size Base Year (Billions) | ~USD 0.5 (2025) |
| Revenue Forecast (Billions) | ~USD 0.75 (2030) |
| Segments Covered | Product, Indication, End User |
3 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| AMBULATORY SURGICAL CENTERS | 1.07 | 1.17 | 1.22 | 1.26 | 1.32 | 1.39 | 1.47 | 1.57 | 5.2 |
| HOSPITALS | 4.05 | 4.46 | 4.64 | 4.84 | 5.09 | 5.38 | 5.71 | 6.1 | 5.7 |
| OTHER END USERS | 0.14 | 0.15 | 0.16 | 0.16 | 0.16 | 0.17 | 0.18 | 0.19 | 3.9 |
| SPECIALTY CLINICS | 1.37 | 1.5 | 1.55 | 1.6 | 1.67 | 1.76 | 1.85 | 1.97 | 4.9 |
| TOTAL | 6.62 | 7.28 | 7.55 | 7.87 | 8.25 | 8.69 | 9.22 | 9.83 | 5.4 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| OLYMPUS CORPORATION | Japan | Public Company | Gastrointestinal Solutions,Urology,Respiratory, |
| MEDTRONIC | Ireland | Public Company | Cardiovascular Portfolio,Neuroscience Portfolio,Medical Surgical Portfolio (incl. Diabetes), |
| FUJIFILM HOLDINGS CORPORATION | Japan | Public Company | Healthcare (medical systems, CDMO, pharma, regenerative medicine, cosmetics/supplements),Electronics (display/touch, semiconductor and image sensor materials, storage/archiving, industrial equipment, fine chemicals),Business Innovation (office equipment, document solutions, graphic communications, inkjet heads), |
| BOSTON SCIENTIFIC CORPORATION | United States | Public Company | Cardiovascular (structural heart, CRM, peripheral interventions, oncology),MedSurg – Endoscopy (GI, pancreaticobiliary, infection prevention, single-use scopes),MedSurg – Urology and Pelvic Health, |
| SUMITOMO BAKELITE CO., LTD. | Japan | Public Company | Semiconductor encapsulation and substrate materials,Phenolic molding compounds and industrial resins,Copper-clad laminates (phenolic and epoxy), |
| CREO MEDICAL GROUP PLC | United Kingdom | Public Company | CROMA platform and capital equipment,Speedboat Inject and multimodal endoscopic instruments,MicroBlate Fine and MicroBlate Flex ablation devices, |
| HOYA CORPORATION | Japan | Public Company | Eyeglasses and ophthalmic lenses,Contact lenses and Eyecity retail,Intraocular lenses and surgical ophthalmology, |
| CONMED CORPORATION | United States | Public Company | Orthopedic & Sports Medicine (BioBrace, Y-Knot, TruShot, Hall power tools),General Surgery (AirSeal insufflation, Buffalo Filter smoke, endomechanical),Endoscopic Technologies (GI therapeutic and diagnostic), |
| STERIS | Ireland | Public Company | Healthcare sterilization and washer-disinfectors,Endoscope reprocessing systems and consumables,Operating room equipment and integration, |
Olympus Corporation is a Japanese public company founded in 1919 with 28,138 employees. The company operates as a diversified manufacturer with significant operations in medical devices and imaging technology.
Medtronic is a public company headquartered in Ireland, founded in 1949, with approximately 95,000 employees. It is a global leader in medical technology, services, and solutions.
Fujifilm Holdings Corporation is a Japanese public company established in 1934 with 73,526 employees. The company operates across imaging, information, and document solutions, as well as healthcare and materials sectors.
Boston Scientific Corporation is a United States-based public company founded in 1979 with 59,000 employees. It specializes in the development and manufacture of medical devices and technologies.
Sumitomo Bakelite Co., Ltd. is a Japanese public company founded in 1932 with 7,524 employees. The company manufactures advanced materials and components for various industrial applications.
Creo Medical Group PLC is a United Kingdom-based public company founded in 2003 with 104 employees. The company develops and commercializes medical devices and technologies.
Hoya Corporation is a Japanese public company established in 1941 with 37,752 employees. The company manufactures optical products, medical devices, and precision equipment.
CONMED Corporation is a United States-based public company founded in 1970 with 3,900 employees. The company designs, manufactures, and sells medical devices and equipment for surgical and patient monitoring applications.
STERIS is a public company headquartered in Ireland, founded in 1985. The company provides sterilization and contamination control products and services for healthcare and industrial markets.
Spain's ESD market is valued at $5.2 million in 2025 and is expected to grow to $7.6 million by 2030.
Spain's ESD market is projected to grow at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2030.
Key drivers include Spain's aging population, rising gastrointestinal cancer prevalence, improved endoscopist training, favorable reimbursement policies, and integration of ESD into standard treatment protocols.
Spain's well-established healthcare infrastructure, favorable reimbursement environment, and emphasis on minimally invasive procedures create a supportive ecosystem for ESD technology adoption and clinical implementation.
Spain's aging population and patients with early-stage gastrointestinal cancers represent the primary beneficiaries of ESD procedures, driving market demand across Spanish healthcare institutions.
The study focused on estimating the current size of the endoscopic submucosal dissection (ESD) market. We conducted thorough secondary research to gather information about the market. The next step involved validating our findings, assumptions, and estimates through primary research by consulting industry experts throughout the value chain. We used various approaches, including top-down and bottom-up methods, to calculate the total market size. Subsequently, we applied market breakdown and data triangulation techniques to estimate the sizes of different segments and subsegments within the ESD market.
This research study heavily utilized secondary sources, including directories and databases such as Dun & Bradstreet, Bloomberg Businessweek, Factiva, whitepapers, and company documents. The purpose of the secondary research was to identify and gather information for a comprehensive, technical, market-oriented, and commercial analysis of the endoscopic submucosal dissection (ESD) market. It also aimed to collect vital information about leading industry players, market classification, and segmentation according to industry trends, down to the most granular levels, as well as geographic markets and key developments related to the market. Additionally, a database of key industry leaders was created based on the findings from the secondary research.
During the primary research process, a variety of supply-side and demand-side sources were interviewed to gather both qualitative and quantitative information for this report. On the supply side, primary sources included industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, engineers, and other key executives from various companies and organizations operating in the ESD market. On the demand side, primary sources encompassed hospitals, clinics, researchers, lab technicians, purchasing managers, and stakeholders from corporate and government bodies.
Breakdown of Primary Interviews
Note 1: C-level executives include CEOs, COOs, and CTOs.
Note 2: Others include sales, marketing, and product managers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the ESD market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

The entire market was split into three segments when the market size was determined. Data triangulation and market breakdown processes were used where necessary to complete the entire market engineering process and arrive at precise statistics for all segments.
Approach to derive the market size and estimate market growth.
Using secondary data from paid and unpaid sources, the market rankings for the major players were determined following a thorough analysis of their sales of ESD. Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.
Endoscopic submucosal dissection (ESD) is an advanced therapeutic endoscopy technique for superficial gastrointestinal neoplasms. In endoscopic submucosal dissection, the equipment includes different types of knives, forceps, snares, and a few other products that support the procedure, as well as accessories used to ease the handling of instruments during surgeries.
Full forecast, segment splits, and company analysis for all Endoscopic Submucosal Dissection/ESD Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report